Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of

Soleno launched VYKAT XR commercially and pulled in $190 million in revenue by year's end, including $92 million in Q4 alone. That hockey-stick trajectory caught Neurocrine's attention, making it one of the faster-growing rare disease launches in recent memory.

Why Neurocrine Needed This

Neurocrine isn't struggling. Its flagship drug, INGREZZA (valbenazine), treats tardive dyskinesia and Huntington's disease chorea. It generated a massive $2.51 billion in 2025 revenue. The company also has CRENESSITY (crinecerfont), which brought in $301 million last year.

But here's the strategic problem: relying too heavily on one blockbuster is like building your entire fantasy football team around a single quarterback. If anything goes wrong (patent cliffs, new competitors, regulatory surprises), you're exposed.

VYKAT XR gives Neurocrine a third commercial product and, more importantly, a foothold in rare disease and endocrinology. Prader-Willi sits at the intersection of neuroscience and metabolic disease, so it's not a random detour. It's adjacent territory.

And there's a European catalyst on the horizon. The EMA validated Soleno's marketing application in May 2025, meaning a European approval could add another layer of revenue growth that Neurocrine's commercial infrastructure is well-positioned to capture.

The Rare Disease Premium Is Real

Let's talk about valuation for a second. Neurocrine is paying roughly 15 times Soleno's 2025 revenue for a drug that's been on the market for less than a year. That sounds steep until you consider the math of rare disease.

The PWS treatment market across the seven major markets already exceeded $600 million in 2023, and that was before VYKAT XR existed. Growth hormone therapy, the previous standard of care, costs $50,000 to $60,000 per year and only addresses height and body composition in children. It does nothing for the most dangerous symptom: the hunger itself.

With roughly 25,000 diagnosed patients across major markets and better diagnostics expanding that number every year, VYKAT XR has room to grow into a genuine blockbuster. Rare disease drugs also tend to face less pricing pressure and enjoy longer commercial lives, which is why acquirers keep paying up for them.

What's at Stake

Neurocrine CEO Kyle W. Gano framed the deal around portfolio diversification and reaching more patients. Soleno CEO Anish Bhatnagar pointed to Neurocrine's commercial muscle as the key to expanding VYKAT XR's reach. The corporate-speak aside, the logic makes sense: Soleno built a great drug, and Neurocrine has the infrastructure to maximize it.

The real question is execution. Neurocrine is funding the deal with cash and "modest prepayable debt," which suggests the balance sheet can absorb it without too much strain. But integrating a rare disease franchise into a neuroscience-focused organization isn't trivial. Different patient populations, different physician networks, different payer dynamics.

Still, if VYKAT XR keeps climbing, this deal could look like a bargain in hindsight. Neurocrine would have a three-product portfolio generating well north of $3 billion annually, with diversified revenue streams across all three.

For the roughly 350,000 to 400,000 people worldwide living with Prader-Willi syndrome, the calculus is simpler. A bigger company with deeper pockets now owns the only approved drug that addresses their most debilitating symptom. If that means faster global access and continued investment in the science, the $2.9 billion price tag might be the best news this community has gotten in years.

The Kidney Drug That Wasn't Supposed to Get Approved

Filspari just became the first FDA-approved treatment for FSGS, a rare kidney disease that's been without an approved therapy forever. The twist? The pivotal trial technically missed its main goal. How Travere pulled off the approval anyway is a story worth reading.